Neurology Alert – May 1, 2005
May 1, 2005
View Issues
-
Silencing SOD1 for Mutant Huntingtin Through RNA Interference Results in Neuroprotective Effects
In SOD1(G93A) transgenic mice, a model for familial ALS, intraspinal injection of a lentiviral vector that produces RNAi-mediated silencing of SOD1 substantially retards both the onset and the progression rate of the disease. -
Narcolepsy — An Autoimmune Disorder?
IgG from all narcolepsy patients significantly enhanced bladder contractile responses to the muscarinic agonist carbachol and to neuronally released acetylcholine compared with control IgG (P < 0.0001), whereas contraction of the sympathetically innervated vas deferens was unaltered. -
Cluster Headache vs Paroxysmal Hemicrania: A Distinction With a Therapeutic Difference
The therapeutic response to indomethacin is the most reliable differential diagnostic criterion for PH vs CH. -
Pregnancy and the Myasthenic
In 15%, and without correlation to maternal disease severity or antibody level, neonatal MG due to the transplacental transfer of maternal antibodies results in transient weakness of the newborn that resolves within 12 weeks. -
Selective Nerve Root Injection
SNRIs may be performed safely with only minor side effects to be expected -
Rasagiline in Advanced Parkinson’s Disease
Once-daily rasagiline reduces mean daily off-time and improves symptoms of Parkinsons disease in levodopa-treated patients with motor fluctuations, an effect similar to that of entacapone. -
Clinical Briefs in Primary Care Supplement
-
Pharmacology Watch: The FDA Pulls Another COX-2 Inhibitor Off the Market
The FDA has asked Pfizer to withdraw valdecoxib (Bextra) from the market due to safety concerns.